

December 30, 2014

STATEMENT ON A NONPROPRIETARY NAME ADOPTED BY THE USAN COUNCIL

USAN (BC-18)

TESEVATINIB

PRONUNCIATION

tes" e va' ti nib

THERAPEUTIC CLAIM


Treatment of cancer and polycystic kidney disease

CHEMICAL NAMES

1. 4-Quinazolinamine, *N*-(3,4-dichloro-2-fluorophenyl)-6-methoxy-7-[[[(3 α ,5 β ,6 α)-octahydro-2-methylcyclopenta[*c*]pyrrol-5-yl]methoxy]-

2. *N*-(3,4-dichloro-2-fluorophenyl)-6-methoxy-7-[[[(3 aR ,5 r ,6 aS)-2-methyloctahydrocyclopenta[*c*]pyrrol-5-yl]methoxy}quinazolin-4-amine

STRUCTURAL FORMULA



MOLECULAR FORMULA

 $C_{24}H_{25}Cl_2FN_4O_2$

MOLECULAR WEIGHT

491.4

TRADEMARK

None as yet

SPONSOR

Kadmon Corporation, LLC

CODE DESIGNATIONS

KD-019; KD-020

CAS REGISTRY NUMBER

781613-23-8

UNII

F6XM2TN5A1

WHO NUMBER

10079

SCS